| Name of drug |
Bioavailability |
Protein binding |
tmax (hours) |
t1/2 (hours) |
Cmax |
SGLT2 selectivity over SGLT1
|
| Canagliflozin |
65% (300 mg dose) |
99% |
1–2 |
10.6 (100 mg dose); 13.1 (300 mg dose) |
1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) |
250 fold
|
| Dapagliflozin |
78% |
91% |
1–1.5 |
12.9 |
79.6 ng/mL (5 mg dose); 165.0 ng/mL (10 mg dose) |
1200 fold
|
| Empagliflozin |
90–97% (mice); 89% (dogs); 31% (rats) |
86.20% |
1.5 |
13.2 (10 mg dose); 13.3h (25 mg dose) |
259nmol/L (10 mg dose); 687nmol/L (25 mg dose) |
2500 fold
|
| Ertugliflozin |
70-90% |
95% |
0.5-1.5 |
11-17 |
268 ng/mL (15 mg dose) |
2000 fold
|
| Ipragliflozin (50 mg) |
90% |
96.30% |
1 |
15–16 (50 mg dose) |
975 ng/mL |
360 fold
|
| Luseogliflozin |
35.3% (male rats); 58.2% (female rats); 92.7% (male dogs) |
96.0–96.3% |
0.625±0.354 |
9.24±0.928 |
119±27.0 ng/mL |
1650 fold
|